Financhill
Sell
14

CYTK Quote, Financials, Valuation and Earnings

Last price:
$45.86
Seasonality move :
-4.74%
Day range:
$45.51 - $47.42
52-week range:
$44.49 - $84.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1,520.22x
P/B ratio:
61.87x
Volume:
998.3K
Avg. volume:
1.1M
1-year change:
-46.62%
Market cap:
$5.4B
Revenue:
$7.5M
EPS (TTM):
-$5.38

Analysts' Opinion

  • Consensus Rating
    Cytokinetics has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $81.71, Cytokinetics has an estimated upside of 78.63% from its current price of $45.74.
  • Price Target Downside
    According to analysts, the lowest downside price target is $60.00 representing -- downside risk from its current price of $45.74.

Fair Value

  • According to the consensus of 11 analysts, Cytokinetics has 78.63% upside to fair value with a price target of $81.71 per share.

CYTK vs. S&P 500

  • Over the past 5 trading days, Cytokinetics has underperformed the S&P 500 by -2.83% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Cytokinetics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Cytokinetics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Cytokinetics reported revenues of $463K.

Earnings Growth

  • Cytokinetics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cytokinetics reported earnings per share of -$1.36.
Enterprise value:
5B
EV / Invested capital:
--
Price / LTM sales:
1,520.22x
EV / EBIT:
--
EV / Revenue:
1,566.42x
PEG ratio (5yr expected):
-0.66x
EV / Free cash flow:
-12.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$327.5M
Return On Assets:
-54.04%
Net Income Margin (TTM):
-17906.24%
Return On Equity:
--
Return On Invested Capital:
-142.05%
Operating Margin:
-30410.58%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $148.2M $7.8M $3.2M $378K $463K
Gross Profit -$61.1M -$312.4M -$327.5M -$82.2M -$84.1M
Operating Income -$218.9M -$495.8M -$524.6M -$122.3M -$140.8M
EBITDA -$233.9M -$462.6M -$481.9M -$113.6M -$135.8M
Diluted EPS -$3.16 -$5.52 -$5.38 -$1.35 -$1.36
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $418.4M $494.9M $884.3M $561.4M $1B
Total Assets $474.1M $827.5M $1.1B $740.6M $1.4B
Current Liabilities $27.6M $80.9M $76.5M $77.7M $109.8M
Total Liabilities $324.5M $578.5M $1.1B $1.2B $1.4B
Total Equity $149.6M $249M -$16M -$438.8M -$13.9M
Total Debt $134M $141M $608.5M $609M $656M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$246.1M -$438.5M -$404.4M -$96.2M -$101.5M
Cash From Investing -$244M $349.9M -$745.4M $73M -$45.1M
Cash From Financing $505.8M $82.4M $1.1B $54.2M $3.4M
Free Cash Flow -$271.9M -$443M -$407.1M -$96.4M -$102.2M
CYTK
Sector
Market Cap
$5.4B
$44.7M
Price % of 52-Week High
--
51.72%
Dividend Yield
0%
0%
Shareholder Yield
-14.12%
-0.75%
1-Year Price Total Return
-46.62%
-33.41%
Beta (5-Year)
0.817
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $46.76
200-day SMA
Sell
Level $55.44
Bollinger Bands (100)
Sell
Level 48.91 - 55.45
Chaikin Money Flow
Buy
Level 23M
20-day SMA
Sell
Level $47.56
Relative Strength Index (RSI14)
Sell
Level 38.82
ADX Line
Sell
Level 23.13
Williams %R
Neutral
Level -77.9152
50-day SMA
Sell
Level $50.12
MACD (12, 26)
Sell
Level -0.99
25-day Aroon Oscillator
Sell
Level -80
On Balance Volume
Neutral
Level 139.3M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-0.4837)
Sell
CA Score (Annual)
Level (-6.2894)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (7.6916)
Sell
Piotroski F Score (Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Stock Forecast FAQ

In the current month, CYTK has received 7 Buy ratings 4 Hold ratings, and 0 Sell ratings. The CYTK average analyst price target in the past 3 months is $81.71.

  • Where Will Cytokinetics Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Cytokinetics share price will rise to $81.71 per share over the next 12 months.

  • What Do Analysts Say About Cytokinetics?

    Analysts are divided on their view about Cytokinetics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cytokinetics is a Sell and believe this share price will drop from its current level to $60.00.

  • What Is Cytokinetics's Price Target?

    The price target for Cytokinetics over the next 1-year time period is forecast to be $81.71 according to 11 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.

  • Is CYTK A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Cytokinetics is a Buy. 7 of 11 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of CYTK?

    You can purchase shares of Cytokinetics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cytokinetics shares.

  • What Is The Cytokinetics Share Price Today?

    Cytokinetics was last trading at $45.86 per share. This represents the most recent stock quote for Cytokinetics. Yesterday, Cytokinetics closed at $45.74 per share.

  • How To Buy Cytokinetics Stock Online?

    In order to purchase Cytokinetics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Quantum Stocks Should I Buy?
What Quantum Stocks Should I Buy?

The last several years have seen a series of tech…

Will Sirius XM Be a 10-Bagger Stock?
Will Sirius XM Be a 10-Bagger Stock?

Last year, Warren Buffett surprised practically everyone when he acquired…

Will Quantum Computing Disrupt NVIDIA?
Will Quantum Computing Disrupt NVIDIA?

Earlier this month, NVIDIA CEO Jensen Huang seemingly dashed the…

Stock Ideas

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 115x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Buy
59
NUKK alert for Jan 21

Nukkleus [NUKK] is up 7.25% over the past day.

Sell
37
FTAI alert for Jan 21

FTAI Aviation [FTAI] is down 25.44% over the past day.

Sell
30
EDU alert for Jan 21

New Oriental Education & Technology Group [EDU] is down 23.18% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock